Adaptive Biotechnologies Corporation
ADPT
$15.26
-$0.87-5.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.77% | 42.57% | 21.60% | 8.61% | 5.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.77% | 42.57% | 21.60% | 8.61% | 5.10% |
| Cost of Revenue | -1.00% | -65.18% | -67.00% | -66.63% | -63.54% |
| Gross Profit | 92.39% | 3,982.88% | 798.53% | 717.19% | 490.15% |
| SG&A Expenses | 6.16% | 1.43% | -2.50% | -8.87% | -8.66% |
| Depreciation & Amortization | -0.23% | -0.35% | -0.35% | -0.23% | 0.24% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.06% | -3.92% | -7.88% | -11.41% | -10.11% |
| Operating Income | 63.23% | 53.22% | 34.70% | 29.50% | 22.95% |
| Income Before Tax | 62.75% | 59.25% | 43.23% | 34.05% | 29.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.75% | 59.25% | 43.23% | 34.05% | 29.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -140.78% | -116.35% | -92.31% | -30.38% | 90.74% |
| Net Income | 62.69% | 59.22% | 43.21% | 34.05% | 29.19% |
| EBIT | 63.23% | 53.22% | 34.70% | 29.50% | 22.95% |
| EBITDA | 71.13% | 59.10% | 37.33% | 31.40% | 24.13% |
| EPS Basic | 63.63% | 60.03% | 44.49% | 35.36% | 30.45% |
| Normalized Basic EPS | 62.11% | 52.13% | 35.14% | 31.19% | 24.87% |
| EPS Diluted | 63.16% | 59.92% | 44.31% | 35.18% | 30.28% |
| Normalized Diluted EPS | 61.73% | 51.78% | 35.14% | 31.19% | 24.87% |
| Average Basic Shares Outstanding | 3.13% | 2.69% | 2.34% | 2.07% | 1.88% |
| Average Diluted Shares Outstanding | 4.96% | 4.52% | 2.34% | 2.07% | 1.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |